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Oral colon-specific delivery of the intact drug is a proven strategy to improve the 
outcome of treatment with drugs with an unfavorable benefit-toxicity ratio. 
Furthermore, oral colon-specific drug delivery is envisaged as mode to make use of 
the opportunities the colon presents as a porte d’entrée for drug substances with low 
bioavailability upon oral administration. Besides these pharmaceutical applications, 
food technology and colon fermentation research provide niche opportunities for 
oral colon-specific delivery of endogenous substances or nutrients. Although the 
opportunities are broadly acknowledged and considerable research efforts have been 
and are being put into this field, many technological and biopharmaceutical issues 
still remain to be investigated and improved. The aim of the translational research 
described in this thesis was to improve oral colon-specific pulsatile drug delivery 
so pharmacotherapy can be optimized. A new technology to obtain colon-specific 
pulsatile delivery is described (ColoPulse technology). Also new methodologies 
applying stable isotopes are described, which enable in vivo evaluation of the 
performance of colon-specific delivery systems.
In chapter 1 an introduction and review on oral colon-specific drug delivery and 
its possible applications in health care are presented. Controlled-release technologies 
to achieve colon-specific drug delivery are described and divided into three main 
approaches. The first approach is the programmed release. Here, drug release (often 
following a pre-designed release profile) will start after a specific lag-time following 
ingestion of the drug product. The second approach is the triggered release system, 
from which drug release starts after it encounters a specific intraluminal condition. 
The third approach is targeted oral drug delivery, where the aim is to target the 
location of disease. Only a limited number of oral colon-specific drug delivery systems 
have been tested in humans so far. A review of clinical trials in humans assessing the 
release properties of various oral colon-specific drug delivery systems reveals three 
main conclusions. Firstly, the majority of the clinical trials involve a triggered release 
system. Secondly, a minority of studies applied stable isotope technology as method 
of evaluation. Thirdly, most subjects included in the clinical trials were healthy 
volunteers (95%) and not patients.
In chapter 2 a gastro-intestinal simulation system (GISS) is described which 
simulates pH and transit times from the stomach to the proximal colon. It may be 
used to determine the in vitro release profile of pH- and time-controlled dosage forms. 
The GISS enables variation of four parameters which are relevant to drug release in 
vivo: transit time, pH, osmolality and agitation (mechanical stress). We evaluated the 
release kinetics of several modified release products containing mesalazine (Salofalk® 
tablets, Salofalk® granules, Asacol® tablets, Pentasa® tablets and granules) in our 
GISS. The release profiles of all products were in agreement with their technological 
concepts. The percentage of the dose released in the simulated colon is small in 
all products. The GISS proved to be a robust system able to discriminate between 
products which apply different modified-release technologies.
In chapter 3 the development of the ColoPulse-technology is described. The 
ColoPulse-technology is based on the non-percolating incorporation of disintegrants 
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in a coating that further consists of a continuous matrix of pH-responsive polymer 
(Eudragit® S). Extensive in vitro release studies were performed in which coatings 
with different concentrations and disintegrants were studied and compared to 
non-disintegrant containing coatings. In vitro data show that the incorporation of 
swelling agents in a Eudragit® S-coating still allows delayed release in the simulated 
terminal ileum. The pulse time and the robustness could be improved compared to 
conventional Eudragit® S-coatings. The pH-responsiveness of the new coating was 
improved by the incorporation of disintegrants, especially in the range just above the 
pH-threshold of 7.0. Based on the in vitro data comparing different swelling agents, 
Ac-di-sol appeared to be the best performing swelling agent.
A proof of concept study in human subjects was performed to investigate the 
performance of the new system in vivo. Coated capsules containing the stable isotope 
13C6-glucose as the test compound were administered and the occurrence of 
13CO2 
in the breath of the subjects was measured. It could be shown that the coating is 
able to resist the environmental conditions in the stomach and duodenum and delays 
release until deeper parts of the intestines are reached. The start of drug release was 
shown to be dependent on the location of the capsule in the gastrointestinal tract 
and not time-dependent. Furthermore, the capsule is able to maintain a pulsatile 
release profile.
In chapter 4 the development of the ColoPulse-technology for tablets is described. 
The production process was validated, and the effect of core composition on the in 
vitro release and permeability investigated. The release profile of the standard tablet 
core composition, based on the use of cellulose as filler excipient, was independent 
of the coat thickness in a range of 9.0 to 13.2 mg/cm2. The release profile of a 
coated tablet was strongly influenced when cellulose was partly replaced by one of 
the model substances, glucose (loss of sigmoidal release), citric acid (stabilization), 
sodium bicarbonate (destabilization) or sodium benzoate (destabilization). It was 
shown that the film coating is permeable since it was able to take up water in an 
environment with a pH below the pH-threshold. However, this did not cause early 
disintegration of the coating.
In chapter 5 the application of stable isotopes in clinical pharmacology is 
reviewed. Stable isotope technology may be used to assess drug pharmacology (to 
determine the pharmacokinetic profile or mode of action of a drug substance), to 
assess drug products or drug delivery systems (by determination of parameters such 
as the bioavailability or the release profile) or to assess patients in relation to patient-
specific drug treatment. Stable isotopice labeled drugs or diagnostic substances are 
shown to have a limited but distinct place in all three areas of clinical pharmacology.
In chapter 6 the suitability of 13C-urea as a marker substance for the assessment 
of in vivo behavior of oral colon-specific drug delivery systems is described. It was 
hypothesized that release in the colon (urease-rich segment) of 13C-urea from colon-
targeted capsules would lead to the fermentation of 13C-urea by bacterial ureases 
into 13CO2. Subsequent absorption in the blood circulation and distribution would 
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lead to detectable 13C (as 13CO2) in breath. If however release of 
13C-urea occurs in 
the small intestine (urease-poor segment), detectable 13C (as 13C-urea) in blood was 
expected and no breath 13C (as 13CO2). In this proof-of-concept study it was shown 
that 13C-urea is able to provide information on both the release kinetics of a colon-
specific delivery system and the location of release. In all subjects 13CO2 exhalation 
was observed, which indicated the availability of 13C-urea in urease-rich segments 
being the cecum or the colon. The total recovery of the 13C-label averaged 99%, 
indicating that by sampling breath and blood a complete picture can be obtained.
In chapter 7 the release profile of a ColoPulse-capsule was assessed by a 
combination of conventional kinetics of a marker substance in blood and site-
specific signaling by stable isotope technology. The study was designed as a two 
period (uncoated versus coated capsule) crossover single dose bioavailability study in 
healthy subjects. The 13C-recovery data after oral administration of 13C-urea using the 
ColoPulse delivery system showed a delayed sigmoid release in all subjects with a lag 
time of >3 hours (median: 330 min.). Release was achieved in a urease-containing 
intestinal segment in all healthy subjects. Complete release in the ileocolonic region 
was achieved in 10 of 11 subjects. The ColoPulse-technology showed the possibility 
to enable specific and reliable drug delivery in the ileocolonic region in healthy 
volunteers.
In chapter 8 a proof-of-concept study is described to demonstrate the feasibility 
of the dual-isotope strategy to determine the release profile of ColoPulse-capsules in 
a one-day, non-invasive dual-label stable isotope study design. Application of a dual-
label stable isotope strategy of 15N2- and 
13C-urea was proved to be suitable for the 
evaluation of local bioavailability of colon drug delivery systems. Since both isotopes 
can be taken at the same time, day-to-day variation in urea kinetics is eliminated and 
study power is increased.
Compared with the conventional two-period study design, our approach reduces 
clinical study costs by a decrease in study run through time (one period instead of 
two) and in sample-load by omitting blood-samples, reducing breath samples by 50% 
and only taking one urine sample. The feasibility study showed that combination of 
breath and a single urine sample provides sufficient information to assess ColoPulse-
capsules in vivo without radioactive exposure in a non-invasive, low-cost study design.
In chapter 9 it is concluded that the technological and biopharmaceutical 
development and characterization of the new ColoPulse technology for drug delivery 
in the colon has been performed to a significant extent. Also a practical method for 
in vivo evaluation or confirmation of the release profile has been developed. The 
research work presented in this thesis, opens the way for investigator-initiated proof-
of-concept clinical studies with active substances to improve treatment of diseases 
such as ulcerative colitis, Crohn’s disease or obesitas utilizing the ColoPulse technology. 
Also experiments to increase insight in the possibilities of oral administration of 
biologicals (such as peptides and heparin) and the role of colon fermentation in 
health can now be set up and executed in vivo.

